OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) announced that the Company’s abstract illustrating research on its novel therapeutic cancer vaccine, has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) could very well storm Wall Street with its prostate cancer vaccine trials. The company has been making great strides in finding a cure for prostate cancer. Last month, OBMP announced that In the ongoing Phase 1 clinical trial, ProscaVax is being evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients. Per protocol, 20 patients are expected to be enrolled in the 1a portion of the study, with therapy consisting of six ProscaVax induction vaccinations at a single dose. To date, 16 prostate cancer patients have enrolled in the trial.

Let’s take a quick look at the technical chart for OBMP.

[intr_chart ticker=OBMP src=””]

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend. However, more positive data could very well grab the eyes of big boys on WallStreet leading to a buying frenzy.

Shares of Pulmatrix Inc (NASDAQ:PULM) are up by more than 69%. PULM had earlier announced that it has entered into a definitive agreement with several institutional investors to purchase an aggregate of approximately $5.0 million of shares of common stock in a registered direct offering. PULM us a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases.
[intr_chart ticker=PULM src=””]
The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is in the Top 1%. Long term indicators mostly agree with the trend.